AIDS 2026 Wednesday July 29 Also Features Gilead Sciences 52-Week Open-Label Extension (OLE) Data From the Phase 3 PURPOSE 1 and PURPOSE 2 Trials of Twice-Yearly Subcutaneous Lenacapavir (Yeztugo) for HIV Prevention (Pre-Exposure Prophylaxis, PrEP): Continued High Efficacy, High Adherence, and Consistent Safety Across the Broad Geographically Diverse Populations Already Using the Drug in 10 Priority Sub-Saharan African Countries
Gilead Sciences (NASDAQ: GILD) presented 52-week open-label extension (OLE) long-term data from the Phase 3 PURPOSE 1 and PURPOSE 2 trials of twice-yearly subcutaneous lenacapavir (Yeztugo, FDA-approved June 2025) for HIV prevention (pre-exposure prophylaxis, PrEP) at AIDS 2026 Wednesday July 29, 2026. PURPOSE 1 documented zero new HIV infections among participants receiving twice-yearly lenacapavir across more than 7,178 person-years of open-label follow-up at Week 52; PURPOSE 2 documented one HIV infection among participants continuing lenacapavir across 5,295 person-years. The 52-week OLE data confirms continued high efficacy, high adherence (participants generally reliably return for the twice-yearly injection), and consistent safety profile across broad and geographically diverse populations. Yeztugo has now been deployed in 10 priority sub-Saharan African countries including South Africa (national program launched June 5, 2026 by President Cyril Ramaphosa in Secunda, Mpumalanga), Zambia, and Eswatini through PEPFAR and Global Fund investments. Generic versions from Dr. Reddy's Laboratories, Hetero Labs, and four other manufacturers are expected in 2027 at approximately $40 per person per year across 120 low- and lower-middle-income countries.